Replies to post #68562 on Biotech Values

[The Borg]

RPRX

[ghmm]

 
 Stock  Product          Stage                   Comments 
 -----  ---------------  ---------------------   ----------------------------- 
 NTII   Viprinex         Phase 3                 Interim analysis January '09.  Stroke Drug, high chance of failure.  Actively said looking for partnership. 
 BPAX   Libigel          Phase 3 ~2010 Submit    Adequate Safety?  Seeking partnership 
 

There are probably a few others that will come to me. IF someone has a better format by all means change it! I think a few comments may be helpful to others in screening their appetite (I would rate both the ones I listed as highly speculative I have no position).

[masterlongevity]

ELN

[bladerunner1717]

Would Chelsea Therapeutics (CHTP) meet your criteria?

Bladerunner

[apljack]

Co.'s without the money to reach the finish line:

I am not a balance sheet expert but actually think that JAV can make it through the NDA for Dyloject in the US, but doubt they will be able to for Ereska without a partner. UK sales of Dyloject were slightly ahead of prjections for their first full quarter and hospital formulary adoption is also ahead of schedule with reorders ahead of schedule. That said, the revenue stream will still be too little too late.

Co.'s that have NO chance to make it, IMO, include COR (CX1717) and PPHM (Bavituximab), but neither of these have reached phase 3 yet.

(Big sigh!) Clearly no early retirement for me.

aj

[donotknowityet]

AEZS